EUCTR2005-005233-35-HU进行中（未招募）不适用
Paclitaxel Poliglumex (CT-2103) vs Paclitaxel for the Treatment of Women with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) who are Performance Status 2
Cell Therapeutics, Inc.0 个研究点目标入组 600 人开始时间: 2005年12月20日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •2.Histologically- or cytologically-confirmed diagnosis of NSCLC. (Note: Sputum cytology alone is not acceptable for cell type. Cytologic specimens obtained by brushings, washings, or needle aspiration of a defined lesion or from a pleural effusion are acceptable).
- •3.ECOG performance score (PS) of 2.
- •4.Patients who meet one of the following criteria:
- •Stage IIIB who are not candidates for combined modality therapy (primary radiation therapy or surgery), or
- •5.Age superior or equal to 18 years.
- •6. Adequate bone marrow function demonstrated by absolute neutrophil count (ANC) > or equal to 1,500/µL and platelet count > or equal to 100,000/µL.
- •7.Adequate renal function demonstrated by creatinine < or equal to 1.5 X the upper limit of normal (ULN).
- •8.Adequate hepatic function demonstrated by all of the following
- •Total bilirubin •If liver metastases are not present, SGOT and SGPT 9.Patients with known brain metastases must have received standard antitumor treatment (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS metastases as defined by the site’s institutional standards. Neurologic function must have been stable for 2 weeks before randomization and patients must either be off steroid therapy for their brain metastases or on a tapering regimen. Patients must have recovered from therapy for their brain metastases.
- •10. Patients who have had major surgery must be fully recovered from the surgery.
- •11.Ability to comply with the visit schedule and assessments required by the protocol.
- •12. For patients of reproductive potential, commitment to use adequate contraception.
- •13. Signed approved informed consent, with understanding of study procedures.
- •14. Agreement to begin study therapy within 8 calendar days after randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •None of the following characteristics may be present:
- •1. Any intolerance to poly-L-glutamic acid, Poloxamer 188, dibasic sodium phosphate, monobasic sodium phosphate (the excipients of CT-2103).
- •2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology.
- •3. Any prior systemic chemotherapy for the treatment of lung cancer. This includes systemic radiosensitizers used to treat brain metastases and any biologic agent.
- •4. Concurrent primary malignancies except for carcinoma in situ or non-melanoma skin cancer.
- •5. Grade 2 or greater neuropathy.
- •6. Evidence of significant unstable neurological symptoms within the 4 weeks before study randomization. (If unstable neurologic symptoms resulted from brain metastases, patient must meet inclusion criteria number 9).
- •7. Clinically significant active infection for which active therapy is underway.
- •8. Investigational therapy within 4 weeks before randomization, unless local requirements are more stringent.
- •9. Unstable medical conditions including unstable angina or myocardial infarction within the past 6 months before randomization. Patients with evidence of cardiac conduction abnormalities are eligible if their cardiac status is stable.
- •10. Pregnant women or nursing mothers.
- •11. Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.
研究者
相似试验
进行中（未招募）
不适用
Paclitaxel Poliglumex (CT-2103) vs Paclitaxel for the Treatment of Women with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) who are Performance Status 2EUCTR2005-005233-35-GBCell Therapeutics, Inc.600
进行中（未招募）
不适用
Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/mlEUCTR2007-004167-22-HUCell Therapeutics, Inc.450
招募中
2 期
Study of Paclitaxel and Carboplatin chemotherapy in metastatic breast carcinomaCTRI/2023/03/051117ALL INDIA INSTITUTE OF MEDICAL SCIENCES Jodhpur
撤回
3 期
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mLNSCLCNCT00576225CTI BioPharma
进行中（未招募）
1 期
A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancerAdvanced, recurrent epithelial ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2006-007013-20-DKOnkologisk afdeling R and the Unit for Experimental Chemotherapy70